RSV LID ΔM2-2 1030s
/ Sanofi, National Institute of Allergy and Infectious Diseases
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 16, 2025
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
(clinicaltrials.gov)
- P1 | N=81 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Apr 2024
Trial completion • Trial completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 1
Of
1
Go to page
1